Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gossamer Bio (GOSS) Cash & Current Investments (2022 - 2025)

Gossamer Bio (GOSS) has 4 years of Cash & Current Investments data on record, last reported at $180.2 million in Q3 2025.

  • For Q3 2025, Cash & Current Investments fell 44.89% year-over-year to $180.2 million; the TTM value through Sep 2025 reached $180.2 million, down 44.89%, while the annual FY2024 figure was $294.5 million, 1.73% up from the prior year.
  • Cash & Current Investments reached $180.2 million in Q3 2025 per GOSS's latest filing, down from $212.9 million in the prior quarter.
  • Across five years, Cash & Current Investments topped out at $354.5 million in Q2 2024 and bottomed at $19.1 million in Q1 2022.
  • Average Cash & Current Investments over 4 years is $213.0 million, with a median of $238.3 million recorded in 2024.
  • Peak YoY movement for Cash & Current Investments: soared 958.83% in 2023, then crashed 44.89% in 2025.
  • A 4-year view of Cash & Current Investments shows it stood at $255.7 million in 2022, then rose by 13.23% to $289.5 million in 2023, then increased by 1.73% to $294.5 million in 2024, then tumbled by 38.81% to $180.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash & Current Investments were $180.2 million in Q3 2025, $212.9 million in Q2 2025, and $257.9 million in Q1 2025.